$JBIO 8-K SEC Filings

Filed On	Filing
30 Sep 2026	8-K: Other Events On September 30, 2026, Jade Biosciences, Inc. (“Jade”) announced preclinical data characterizing JADE301, its anti-interferon beta (“IFN-ß”) monoclonal antibody in development for dermatomyositis (“DM”), a rare, chronic and debilitating ...
10 Aug 2026	8-K: Results of Operations and Financial Condition
01 Jul 2026	8-K: Entry into a Material Definitive Agreement
26 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
11 Jun 2026	8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
04 Jun 2026	8-K: Other Events
01 Jun 2026	8-K: Regulation FD Disclosure; Other Events
07 May 2026	8-K: Results of Operations and Financial Condition
22 Apr 2026	8-K: Departure/Election of Directors or Officers; Compensation
02 Apr 2026	8-K: Departure/Election of Directors or Officers; Compensation
06 Mar 2026	8-K: Results of Operations and Financial Condition
05 Jan 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
15 Dec 2025	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
14 Nov 2025	8-K: Results of Operations and Financial Condition; Other Events
07 Oct 2025	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
09 Sep 2025	8-K: Departure/Election of Directors or Officers; Compensation
13 Aug 2025	8-K: Results of Operations and Financial Condition
01 Jul 2025	8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more
14 May 2025	8-K: Completion of Acquisition or Disposition of Assets; Results of Operations and Financial Condition +1 more
01 May 2025	8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +9 more

Comments